HomeAI · summaries
Storia in 18 fonti
'Grand Slam' in Pancreatic Cancer: Novel Pill Doubles Survival
RASolute 302 findings herald a new standard of care in previously treated patients
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
pbs.org
Pancreatic cancer is deadly and difficult to treat. A new pill could change that
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
- ·
healio.com
Daraxonrasib offers ‘transformational’ benefit in metastatic pancreatic cancer
CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the buzz it created among ASCO Annual Meeting…
